Jochen Utikal
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1395.
01.09.2023Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
01.09.2023Nat Cancer 2023; 4:1395
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1292-1308.
31.07.2023Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
31.07.2023Nat Cancer 2023; 4:1292-1308
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40:3741-3749.
16.06.2022Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
16.06.2022J Clin Oncol 2022; 40:3741-3749
Garbe Claus, Keim Ulrike, Amaral Teresa, Berking Carola, Eigentler Thomas Kurt, Flatz Lukas, Gesierich Anja, Leiter Ulrike, Stadler Rudolf, Sunderkötter Cord, Tüting Thomas, Utikal Jochen, Wollina Uwe, Zimmer Lisa, Zouboulis Christos C, Ascierto Paolo Antonio, Eggermont Alexander M M, Grob Jean-Jacques, Hauschild Axel, Sekulovic Lidija Kandolf, Long Georgina V, Luke Jason J, Michielin Olivier, Peris Ketty, Schadendorf Dirk, Kirkwood John M, Lorigan Paul C, Central Malignant Melanoma Registry (CMMR)
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Wagner N, Utikal J, Umansky V, Garbe C, Schadendorf D, Holland-Letz T, Herpel E, Sucker A, Lichtenberger R, Funder A, Kehrel C, Kemper C, Schuermans V, Tarnanidis K, Reith M, Gries M, Weide B, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer 2019; 7:343.
05.12.2019Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
05.12.2019J Immunother Cancer 2019; 7:343
Wagner Nikolaus, Utikal Jochen, Umansky Viktor, Garbe Claus, Schadendorf Dirk, Holland-Letz Tim, Herpel Esther, Sucker Antje, Lichtenberger Ramtin, Funder Anne, Kehrel Coretta, Kemper Charlotte, Schuermans Valerie, Tarnanidis Kathrin, Reith Maike, Gries Mirko, Weide Benjamin, Gebhardt Christoffer
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Wagner N, Utikal J, Enk A, Umansky V, Garbe C, Naeher H, Holland-Letz T, Busch C, Ikenberg K, Eubel J, Herpel E, Pflugfelder A, Lichtenberger R, Kehrel C, Tarnanidis K, Reith M, Weide B, Gebhardt C. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int J Cancer 2015; 137:2607-17.
14.07.2015Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
14.07.2015Int J Cancer 2015; 137:2607-17
Wagner Nikolaus, Utikal Jochen, Enk Alexander, Umansky Viktor, Garbe Claus, Naeher Helmut, Holland-Letz Tim, Busch Christian, Ikenberg Kristian, Eubel Jana, Herpel Esther, Pflugfelder Annette, Lichtenberger Ramtin, Kehrel Coretta, Tarnanidis Kathrin, Reith Maike, Weide Benjamin, Gebhardt Christoffer